The schedule begins with a fireside chat at the Morgan Stanley Biotech Without Borders Series on July 28, 2026. Following this digital appearance, Woo will shift to an in-person engagement at the 2nd Annual Evercore China Biotech Summit. Held at The Ritz-Carlton in Pudong on August 18, 2026, this session will feature a formal presentation and a subsequent question-and-answer period for institutional stakeholders.

These appearances arrive as the biopharmaceutical firm continues to scale its integrated commercialization platform. Beyond its existing therapeutic portfolio, Everest Medicines is currently leveraging a proprietary mRNA platform to advance experimental treatments, including mRNA in vivo CAR-T therapies and cancer vaccines. The upcoming discussions are expected to provide further clarity on the company’s plans for global expansion and its lifecycle management strategy for high-value assets.